Volume 2, Issue 4, July 2016, Page: 59-66
Asthma Chronic Obstructive Pulmonary Disease Overlap Syndrome (ACOS): Where We Stand
Joyce Akwe, Atlanta Veterans Affairs Medical Center, Emory University School of Medicine, Department of Medicine, Atlanta GA, USA
Amy Miller, Atlanta Veterans Affairs Medical Center, Emory University School of Medicine, Department of Medicine, Atlanta GA, USA
Received: May 25, 2016;       Accepted: Jun. 3, 2016;       Published: Jul. 5, 2016
DOI: 10.11648/j.ijcems.20160204.12      View  3195      Downloads  71
Abstract
Asthma-Chronic obstructive pulmonary disease overlap syndrome (ACOS) or ASCOS is a frequently encountered clinical syndrome. It is identified by the clinical features that it shares with asthma and COPD. There is no clear consensus definition yet for this medical syndrome. ACOS has not been extensively studied partly because of the absence of clarity of its clinical significance and because of the lack of a clear definition for this syndrome. ACOS is characterized by persistent airflow limitation with several features usually associated with asthma and several features usually associated with chronic obstructive pulmonary disease (COPD). It has been described and named differently by different authors. Some of the commonly encountered names are asthmatic bronchitis, asthma of the elderly, patients with COPD and a prominent asthmatic component, asthma that complicates COPD, asthma with permanent obstruction, COPD with a reversible component and asthma-COPD overlap syndrome. In most obstructive lung disease trials patients with overlap syndrome are excluded because they are not strictly asthmatic per the study inclusion criteria or they are not strictly chronic obstructive pulmonary disease patients. With no clear consensus on the definition and few studies on its genetics or pathophysiology, it is difficult to create management guidelines for this group of patients. Patients with ACOS have been found to have higher risk not only for exacerbations, but also for hospitalizations. Global Initiative for Chronic Obstructive Lung Disease (Gold) and the Global Initiative for Asthma (GINA) have suggested a stepwise diagnostic and management criteria for patients with ACOS.
Keywords
Asthma COPD Overlap Syndrome (ACOS), Definition, Pathophysiology, Approach, Management
To cite this article
Joyce Akwe, Amy Miller, Asthma Chronic Obstructive Pulmonary Disease Overlap Syndrome (ACOS): Where We Stand, International Journal of Clinical and Experimental Medical Sciences. Vol. 2, No. 4, 2016, pp. 59-66. doi: 10.11648/j.ijcems.20160204.12
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases. American Thoracic Society. Definitions and classfication of chronic bronchitis, asthma, and pulmonary emphysema. Am. Rev. Respir. Dis. 1962; 85: 762-769.
[2]
Zeki AA, Schivo M, Chan A, et al. The Asthma-COPD Overlap Syndrome: A Common Clinical Problem in the Elderly. J Allergy. 2011; 2011: 861926.
[3]
Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009; 64(8): 728–735.
[4]
Hardin M, Silverman EK, Barr RG et al.; COPDGene Investigators. The clinical features of the overlap between COPD and asthma. Respir. Res. 2001;12: 127. doi: 10.1186/1465-9921-12-127
[5]
Lange P, Parner J, Vestbo J, et al. A 15 year follow-up study of ventilatory function in adults with asthma. N Engl J Med. 1998; 339: 1194–2000.
[6]
Soriano JB, Davis KJ, Coleman B, et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest. 2003; 124: 474–81.
[7]
Global Initiative for Asthma. Diagnosis of Diseases of Chronic Airflow Limitation: Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS). http://www.ginasthma.org. Published 2015, Accessed June 2016.
[8]
Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016. www.goldcopd.org (Accessed on March 20, 2016).
[9]
Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Aten Primaria. 2012; 44: 425-37.
[10]
American Thoracic Society. Standards for diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995; 152: S77-121.
[11]
Soler-Cataluña JJ, Cosío B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol. 2012;48:331-337.
[12]
Chaudhuri R, Livingston E, McMahon AD, et al. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care ed. 2003; 168: 1308–11.
[13]
Louie S, Zeki AA, Schivo M, et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharma¬cotherapeutic considerations. Expert Rev Clin Pharmacol. 2013; 6: 197-219.
[14]
S. Sharma, K. Tantisira, V. Carey et al., “A role for wnt signaling genes in the pathogenesis of impaired lung function in asthma,” American Journal of Respiratory and Critical Care Medicine.2010;181(4): 328–336.
[15]
N. Kneidinger, A. O¨. Yildirim, J. Callegari et al., “Activation of the WNT/β-catenin pathway attenuates experimental emphysema,” American Journal of Respiratory and Critical Care Medicine. 2001: 183(6): 723–733.
[16]
De Marco R, Pesce G, Marcon A, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population. PLoS One. 2013; 8: e62985.
[17]
Marsh SE, Travers J, Weatherall M, et al. Proportional classifications of COPD phenotypes. Thorax 2008; 63: 761–7.
[18]
D. P. Tashkin, B. Celli, M. Decramer et al., “Bronchodilator responsiveness in patients with COPD,” European Respiratory Journal. 2008; 31(4): 742–750.
[19]
P. Kauppi, H. Kupiainen, A. Lindqvist et al., “Overlap syndrome of asthma and COPD predicts low quality of life,” Journal of Asthma. 2011; 48(3): 279–285.
[20]
Miravitlles M, Soriano JB, Ancochea J, et al. Characterisation of the overlap COPD-asthma phenotype. Focus on physical activity and health status. Respir Med. 2013; 107: 1053-60.
[21]
Menezes AM, de Oca MM, Perez-Padilla R, et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma. Chest. 2014; 145: 297-304.
[22]
Andersén H, Lampela P, Nevanlinna A, et al. High hospital burden in overlap syndrome of asthma and COPD. Clin Respir J. 2013; 7: 342-6.
[23]
Mannino D. M., Gagnon R. C., Petty T. L., and Lydick E., “Obstructive lung disease and low lung function in adults in the United States: data from the national health and nutrition examination survey, 1988–1994,” Archives of Internal Medicine.2000; 160(11): 1683–1689.
[24]
Shaya F. T., Dongyi D., Akazawa M. O. et al., “Burden of concomitant asthma and COPD in aMedicaid population.” Chest.2008; 134(1): 14–19.
[25]
Hardin M, Silverman EK, Barr RG, et al. COPDGene Investigators. The clinical features of the overlap between COPD and asthma. Respir Res. 2011; 12: 127.
[26]
Orie NG. The dutch hypothesis. Chest. 2000; 117: 299S.
[27]
Papaiwannou, Antonis, Paul Zarogoulidis, Konstantinos Porpodis, et. al. "Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature review." J Thorac Dis. 2014; 6(Suppl 1): S146–S151. doi: 10.3978/j.issn.2072-1439.2014.03.04
[28]
Chanez P, Vignola AM, O’Shaugnessy T, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med. 1997; 155: 1529-34.
[29]
Shaw DE, Berry MA, Hargadon B, et al. Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest. 2007; 132: 1871-5.
[30]
Bumbacea D, Campbell D, Nguyen L, et al. Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 2004; 24: 122-8.
[31]
Vonk JM, Jongepier H, Panhuysen CIM, et al. Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up. Thorax. 2003; 58: 322-7.
[32]
Iwamoto H, Gao J, Koskela J, et al. Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap. Eur Respir J. 2014; 43: 421-9.
[33]
Soriano JB, Visick GT, Muellerova H, et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005; 128: 2099-107.
[34]
Lindner K., Panaszek B., and Machaj Z., “Asthma in the elderly,” Polskie Archiwum Medycyny Wewnetrznej.2007; 117(8): 350–354.
[35]
Beeh K. M., Kornmann O., Beier J., Ksoll M., and Buhl R., “Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary Disease,” Respiratory Medicine. 2004; 98(7): 591–597.
[36]
Burrows B, Barbee RA, Cline MG, Knudson RJ, Lebowitz MD. Characteristics of asthma among elderly adults in a sample of the general population. Chest. 1991; 100(4): 935–942.
[37]
Braman SS, Kaemmerlen JT, Davis SM. Asthma in the elderly: a comparison between patients with recently acquired and long-standing disease. American Review of Respiratory Disease. 1991; 143(2): 336-40.
[38]
Stick S. Pediatric origins of adult lung disease: The contribution of airway development to pediatric and adult lung disease. Thorax. 2000;55: 587-94
[39]
Price D, Musgrave SD, Shepstone L et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N. Engl. J. Med. 2011; 364(18): 1695–1707.
[40]
Yanli Gaoa, Xiaoli Zhaia, Kun Lia. Et al. Asthma COPD Overlap Syndrome on CT Densitometry: A Distinct Phenotype from COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease.2016; Published online: 08 Jan 201. DOI:10.3109/15412555.2015.1102874.
[41]
Dupont L, Potvin E, Korn D et al.; Singulair as Complementary Therapy to Fixed Association in Real life Study Group. Improving asthma control in patients suboptimally controlled on inhaled steroids and long-acting beta2-agonists: addition of montelukast in an open-label pilot study. Curr. Med. Res. Opin. 2005; 21(6): 863–869.
[42]
Woodruff PG, Albert RK, Bailey WC et al.; COPD. Clinical Research Network. Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. COPD. 8(1): 21–29.
[43]
Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am. J. Respir. Crit. Care Med. 1997; 156: 737–743.
[44]
Jonas DE, Wines RCM, DelMonte M et al. In: Drug Class Review: Controller Medications for Asthma: Final Update 1 Report.2011. OR, USA.
[45]
Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet; 2009: 374(9691): 685–694.
[46]
Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD. Respir. Res. 2011; 12: 18
[47]
Barnes PJ. Theophylline for COPD. Thorax.2006: 61(9), 742–744.
Browse journals by subject